CARsgen Therapeutics Holdings Limited
CARsgen Therapeutics Holdings Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies and solid tumors in China and t…
Biotechnology
CN, Shanghai [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | -0.62 | 9361.49 | 9420.33 | |
| Graham Fair Price | 0.00 | 149.83 | 149.83 | |
| PEG | inf | 0.00 | 0.45 | |
| Price/Book | -26.78 | < 0.005 | < 0.005 | |
| Price/Cash Flow | 26.78 | -20.18 | -27.57 | |
| Prices/Earnings | 26.78 | -4.61 | -6.30 | |
| Price/Sales | 0.00 | 0.00 | 0.00 | |
| Price/FCF | 26.78 | -20.18 | -27.57 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Somewhat Weak
Fundamentals
Profitability
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | 0.00 | 0.00 | 0.00 | |
| Operating Margin | 0.00 | 0.00 | 0.00 | |
| ROA | 0.00 | < 0.005 | < 0.005 | |
| ROE | < 0.005 | < 0.005 | 0.00 | |
| ROIC | < 0.005 | < 0.005 | 0.65 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | 0.17 | -0.34 | -51.14 | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | -0.10 | 0.00 | inf | |
| EPS QOQ | 0.14 | 0.00 | inf | |
| FCF QOQ | -1.10 | 0.00 | inf | |
| Revenue QOQ | 0.00 | 0.00 | 0.00 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Positive
Fundamentals
Leverage & Liquidity
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 0.00 | 0.00 | 0.00 | |
| Days Sales Outstanding (DSO) | 0.00 | 0.00 | 0.00 | |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | |
| Debt/Capitalization | 0.04 | 0.05 | 16.00 | |
| Quick Ratio | 9.43 | 9.54 | 1.16 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Book Value | 3235.96 | 3235.96 | 0.00 | |
| Cash | 3324.29 | 3322.26 | -0.06 | |
| Capex | < 0.005 | < 0.005 | 0.00 | |
| Free Cash Flow | -0.28 | -0.28 | 0.00 | |
| Revenue | 0.00 | 0.00 | 0.00 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Bad
Fundamentals
Financial Health
06 - Financial Health ·
Bad